Peyrin-Biroulet L - Search Results

1

Cancer and inflammatory bowel disease in the elderly.

Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L. Taleban S, et al. Dig Liver Dis. 2016 Oct;48(10):1105-11. doi: 10.1016/j.dld.2016.05.006. Epub 2016 May 20. Dig Liver Dis. 2016. PMID: 27289334 Review.

2

[Circumstances of the diagnosis and clinical course of inflammatory bowel disease].

Peyrin-Biroulet L, Bigard MA. Peyrin-Biroulet L, et al. Rev Prat. 2005 May 15;55(9):962-76. Rev Prat. 2005. PMID: 16052967 Review. French.

3

Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine.

Peyrin-Biroulet L, Rodriguez-Guéant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Guéant JL. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2007 May;102(5):1108-15. doi: 10.1111/j.1572-0241.2007.01170.x. Epub 2007 Mar 13. Am J Gastroenterol. 2007. PMID: 17355415 Review.

4

A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.

Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. Roblin X, et al. Am J Gastroenterol. 2008 Dec;103(12):3115-22. doi: 10.1111/j.1572-0241.2008.01743.x. Am J Gastroenterol. 2008. PMID: 19086961 Retracted. Clinical Trial.

5

Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.

Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Chevaux JB, et al. Inflamm Bowel Dis. 2010 Jun;16(6):916-24. doi: 10.1002/ibd.21147. Inflamm Bowel Dis. 2010. PMID: 19885908

6

Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review.

Oussalah A, Danese S, Peyrin-Biroulet L. Oussalah A, et al. Curr Drug Targets. 2010 Feb;11(2):156-75. doi: 10.2174/138945010790309939. Curr Drug Targets. 2010. PMID: 20210765 Review.

7

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A, Laharie D, Reimund JM, Lémann M, Delaporte E, Colombel JF; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Rahier JF, et al. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1048-55. doi: 10.1016/j.cgh.2010.07.022. Epub 2010 Aug 20. Clin Gastroenterol Hepatol. 2010. PMID: 20728573 Free article.

8

Optimizing thiopurine therapy in inflammatory bowel disease.

Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Chevaux JB, et al. Inflamm Bowel Dis. 2011 Jun;17(6):1428-35. doi: 10.1002/ibd.21494. Epub 2010 Oct 14. Inflamm Bowel Dis. 2011. PMID: 20949566 Review.

9

Is the dose of thioguanine the key to better safety profile?

Chevaux JB, Peyrin-Biroulet L. Chevaux JB, et al. Dig Liver Dis. 2011 Feb;43(2):96-7. doi: 10.1016/j.dld.2010.11.003. Epub 2010 Dec 14. Dig Liver Dis. 2011. PMID: 21156354 No abstract available.

10

Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Bouguen G, Chevaux JB, Peyrin-Biroulet L. Bouguen G, et al. World J Gastroenterol. 2011 Feb 7;17(5):547-56. doi: 10.3748/wjg.v17.i5.547. World J Gastroenterol. 2011. PMID: 21350703 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,036 results

Search Page